Robert Blum Sells 7,500 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert Blum sold 7,500 shares of Cytokinetics stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $70.24, for a total transaction of $526,800.00. Following the completion of the sale, the chief executive officer owned 377,820 shares of the company’s stock, valued at $26,538,076.80. This trade represents a 1.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Stock Up 0.7%

Shares of NASDAQ:CYTK opened at $71.40 on Wednesday. The company’s 50 day moving average price is $79.78 and its two-hundred day moving average price is $72.36. Cytokinetics, Incorporated has a 12-month low of $44.91 and a 12-month high of $88.31. The firm has a market cap of $8.88 billion, a PE ratio of -9.89 and a beta of 0.36.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. The firm’s quarterly revenue was down 57.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.12) earnings per share. On average, research analysts expect that Cytokinetics, Incorporated will post -6 EPS for the current year.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reached a Phase 3 milestone in non-obstructive hypertrophic cardiomyopathy (HCM), highlighting progress in its cardiovascular pipeline and potentially expanding the opportunity for its muscle-directed therapies. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM
• Positive Sentiment: The company presented new Phase 3 data, prompting continued discussion of the pipeline’s value; one analysis characterized CYTK as approximately 34% undervalued. Cytokinetics Presents New Phase 3 Data
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $140 price target, implying substantial upside from the stock’s recent level. The broader analyst consensus remains “Moderate Buy,” with a target near $102.20.
• Neutral Sentiment: Recent quarterly results exceeded expectations, with a loss of $1.50 per share versus the expected $1.63 loss and revenue of $28.62 million versus a $17.59 million estimate. However, revenue declined 57.1% year over year and the company remains unprofitable.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, EVP Andrew Callos sold 10,000 shares for about $702,400, and director B. Lynne Parshall sold 5,000 shares for roughly $357,400. All trades were conducted under pre-arranged Rule 10b5-1 plans, reducing their value as signals of current management sentiment, though the sales may still weigh modestly on investor confidence. Cytokinetics Insider Trading Activity
• Negative Sentiment: Wall Street Zen lowered its rating on CYTK, providing a counterpoint to the more optimistic sell-side outlook.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CYTK. EverSource Wealth Advisors LLC boosted its holdings in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 673 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of Cytokinetics in the 4th quarter valued at $27,000. Kestra Advisory Services LLC acquired a new position in shares of Cytokinetics during the 4th quarter worth $29,000. Quarry LP acquired a new position in shares of Cytokinetics during the 3rd quarter worth $30,000. Finally, Advisory Services Network LLC bought a new stake in shares of Cytokinetics during the 3rd quarter worth $32,000.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CYTK. Barclays lifted their price objective on Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of Cytokinetics in a research report on Monday. Stifel Nicolaus boosted their price target on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Mizuho upped their price objective on shares of Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 24th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cytokinetics has a consensus rating of “Moderate Buy” and an average target price of $102.20.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.